LONDON, May 29 (Reuters) - GlaxoSmithKline hasinvited private equity firms to consider making offers for arange of its older drugs, according to two people with directknowledge of the matter.
The move is part of a reshaping of the drugmaker's business,which also involves a major asset swap deal with Novartis.
Chief Executive Andrew Witty said last month that Britain'sbiggest pharmaceuticals company could dispose of individualmedicines or a broader portfolio of older established products.A GSK spokesman had no further comment on potential disposals onThursday. (Reporting by Ben Hirschler; editing by Jon Boyle)